By Ilan Zipkin
Staff Writer

By now investors should not be surprised when a tool company announces that it plans to develop proprietary products, as the toolkit partnership model has taken a beating in recent years. CuraGen Corp., however, has been quietly on the product track for some time despite only recently announcing its therapeutic antibody deal with Abgenix Inc.